The Kirsten rat sarcoma oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small-cell lung cancer (NSCLC), occurring in approximately 30 % of cases [1]. KRAS mutations are ...

A network meta-analysis was performed to compare the efficacy of immune checkpoint inhibitors (ICIs) with and without chemotherapy, in the first-line management of metastatic non-small cell lung canc...

Szmyd et al. show that DNA repair pathways impact whether cells with DNA lesions arrest in mitosis. The formation of homologous recombination-driven double Holliday junctions elicits mitotic cell deat...

Kosaka et al.1 present an important perspective regarding our manuscript “Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study.”2 In our study, the median progression-free survival (PFS)-2 was 17 months (95% confidence interval: 12–31) following radiotherapy for oligoprogression in metastatic NSCLC. By contrast, the CURB trial by Tsai et al.3 reported a shorter median PFS of 10 months (95% confidence interval: 7.2–not reached) after stereotactic body radiation therapy (SBRT).